Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377361 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 325
- Enrollment target
NCT03377361 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 325 participants.
The verdict
NCT03377361, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Interventions
- DRUG Regorafenib
- BIOLOGICAL Nivolumab
- DRUG Trametinib
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2024-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03377361
The ClinicalTrials.gov registry entry for NCT03377361 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Regorafenib is the first listed.
NCT03377361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03377361 about?
NCT03377361 is a clinical study titled "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread". The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
What is the current status of trial NCT03377361?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 325 participants. The study started on 2018-01-31. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT03377361?
The interventions under investigation include: Regorafenib (DRUG), Nivolumab (BIOLOGICAL), Trametinib (DRUG), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03377361?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.